Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day,
highest approved dose or placebo), WL (10% of body weight, following the established program
used in the Diabetes Prevention Program), or Pio+WL. Participants will be evaluated at
baseline and after 24 weeks of intervention while on a fixed metabolic diet to exclude the
confounding effects of diet and perspiration. The primary endpoint will be change in upH, and
multiple additional endpoints (serum, urine, imaging) will be assessed.